SCHEMBL1086016

SCHEMBL1086016

COc1ccc(OC)c(C(N)=O)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.66
HTT P42858 1/20 0.66
NPSR1 Q6W5P4 1/20 0.66
ALDH1A1 P00352 5/20 0.58
CA1 P00915 2/20 0.57
CA2 P00918 2/20 0.57
CA12 O43570 1/20 0.57
CA7 P43166 1/20 0.57
CA9 Q16790 1/20 0.57
CA14 Q9ULX7 1/20 0.57
ABCG2 Q9UNQ0 1/20 0.57
POLB P06746 1/20 0.57
PDE4A P27815 1/20 0.56
PDE4B Q07343 1/20 0.56
PDE4C Q08493 1/20 0.56
PDE4D Q08499 1/20 0.56
HPGD P15428 2/20 0.53
RAD52 P43351 1/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30052013 1.00 MAPT (0.66) MAPTHTTNPSR1ALDH1A1CA1
Hydrochloric Acid SCHEMBL27585316 0.98 MAPT (0.64) MAPTHTTNPSR1ALDH1A1CA1
SCHEMBL9021036 0.85 SIRT1 (0.51) MAPTHTTNPSR1ALDH1A1CA1
SCHEMBL1034025 0.85 ALDH1A1 (0.68) MAPTHTTALDH1A1CA1CA2
SCHEMBL29624500 0.85 ALDH1A1 (0.68) MAPTHTTALDH1A1CA1CA2
SCHEMBL14538979 0.84 AR (0.49) MAPTHTTNPSR1ALDH1A1ABCG2
SCHEMBL11627742 0.84 MAPK1 (0.56) MAPTHTTNPSR1HPGDMEN1
SCHEMBL12228747 0.84 MAPT (0.82) MAPTHTTNPSR1ALDH1A1CA1
SCHEMBL2835948 0.84 PARP1 (0.55) MAPTHTTNPSR1ALDH1A1CA1
SCHEMBL32667941 0.83 KDM4E (0.66) MAPTHTTNPSR1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12575248-B2 Zinc oxide nanomaterial and preparation method thereof and semiconductor device TCL TECHNOLOGY GROUP CORPORATION (CN) 2026-03-10 US claimed
EP-4167307-B1 ZINC OXIDE NANOMATERIAL AND PREPARATION METHOD THEREFOR, AND SEMICONDUCTOR DEVICE TCL TECH GROUP CORP (CN) 2025-02-05 EP claimed
CN-111875557-B Thiazole derivative and synthesis method thereof 南通大学 2023-06-02 CN claimed
EP-4167307-A1 ZINC OXIDE NANOMATERIAL AND PREPARATION METHOD THEREFOR, AND SEMICONDUCTOR DEVICE TCL Technology Group Corporation (CN) 2023-04-19 EP claimed
CN-113809245-B Zinc oxide nano material, preparation method thereof and semiconductor device TCL科技集团股份有限公司 2022-11-04 CN claimed
US-20220336764-A1 ZINC OXIDE NANOMATERIAL AND PREPARATION METHOD THEREOF AND SEMICONDUCTOR DEVICE U.S. DEPARTMENT OF ENERGY 2022-10-20 US claimed
WO-2021253780-A1 ZINC OXIDE NANOMATERIAL AND PREPARATION METHOD THEREFOR, AND SEMICONDUCTOR DEVICE TCL科技集团股份有限公司 2021-12-23 WO claimed
CN-113809245-A Zinc oxide nano material, preparation method thereof and semiconductor device TCL科技集团股份有限公司 2021-12-17 CN claimed
CN-111875557-A Thiazole derivative and synthesis method thereof 南通大学 2020-11-03 CN claimed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP claimed
EP-1412325-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES BIOVITRUM AB (SE) 2004-04-28 EP claimed
JP-2004505977-A 2004-02-26 JP claimed
US-20030158202-A1 Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders PROXIMAGEN NEUROSCIENCE PLC (GB) 2003-08-21 US claimed
EP-1320531-A2 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2003-06-25 EP claimed
WO-2002100822-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES BIOVITRUM AB (SE) 2002-12-19 WO claimed
WO-2002012242-A2 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2002-02-14 WO claimed
EP-1150565-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION bioscience AG (DE) 2001-11-07 EP claimed
EP-1126833-A2 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2001-08-29 EP claimed
WO-2000045635-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2000-08-10 WO claimed
WO-2000025768-A1 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2000-05-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12575248-B2 Zinc oxide nanomaterial and preparation method thereof and semiconductor device ZRANB2, ZKSCAN2, SLC39A3 MAPT 2260/4885HTT 3789/4885NPSR1 3548/4885
US-20030158202-A1 Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders SULT2A1, SULT1A1, SULT1E1 MAPT 1761/4885HTT 816/4885NPSR1 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.